Cardiac safety of chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults

Six months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.